Net sales totaled $16.2 million in Q2 2025, Net sales increased 23% in the second quarter. This marks the third straight quarter of year-over-year revenue growth. OEM Net Sales-- OEM segment net sales ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Reports Q2 revenue $98.61M vs. $63.14M last year. “The second quarter marked a surge in our growth momentum with net revenues soaring over 50% year-over-year and net income exceeding RMB40 million, ...

Strong margin expansion driven by new revenue streams, enhanced channel mix, and disciplined cost management Perfect Moment Ltd.

Special 250th anniversary designs offer a golden opportunity to grow the hobby and inspire the next generation of ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

Q2 2025 Management View James V. Caruso, President and CEO, stated that Cellectar has made "significant strides across our ...

Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.